PP_1170x120_10-25-21

coronavirus (COVID-19) pandemic

RxImpact Day gains potency amid crisis

RxImpact Day gains potency amid crisis

The importance of retail pharmacy has been thrown into relief by COVID-19, and the National Association of Chain Drug Stores is making the most of the present moment by informing members of Congress and other federal officials about policy matters that affect the profession and its ability to care for patients. The pandemic may have

Walgreens completes first phase of mental health first aid training

Walgreens completes first phase of mental health first aid training

DEERFIELD, Ill. – With a sharply rising need for mental health resources since the onset of the COVID-19 pandemic, Walgreens announced on Wednesday it has completed its first phase of training in Mental Health First Aid, administered by the National Council for Behavioral Health, for all of the company’s health outcomes pharmacists. The training initiative

IRI study says U.S. consumers pessimistic about coming months

IRI study says U.S. consumers pessimistic about coming months

CHICAGO — As IRI continues to monitor COVID-19, its latest analysis, “Consumers Provide Pessimistic View of Coming Months,” finds that U.S. consumers are becoming increasingly concerned about the health crisis and the long-term economic impact. COVID-19 U.S. Implications With nearly 60% of consumers believing the COVID-19 pandemic will last more than three months and 92% believing

CVS Health to provide bonuses, add benefits

CVS Health to provide bonuses, add benefits

WOONSOCKET, R.I. — In recognition of the essential role CVS Health employees are playing as the country faces the COVID-19 pandemic, the company is awarding bonuses to employees who are required to be at CVS facilities to assist patients and customers in this time of unprecedented need. Bonuses will range from $150 to $500 and will be awarded

FDA issues guidance for conducting clinical trials during COVD-19 pandemic

FDA issues guidance for conducting clinical trials during COVD-19 pandemic

WASHINGTON — The U.S. Food and Drug Administration Wednesday has issued a guidance for industry, investigators and institutional review boards conducting clinical trials during the coronavirus (COVID-19) pandemic. The FDA recognizes that the COVID-19 pandemic may impact the conduct of clinical trials of medical products, including drugs, devices and biological products. Challenges may arise, for example,